Real-time prescription monitoring system in Victoria

Size: px
Start display at page:

Download "Real-time prescription monitoring system in Victoria"

Transcription

1 Real-time prescription monitoring system in Victoria Angela Liu RUSSELL KENNEDY LAWYERS New legislation in Victoria to implement mandatory real-time prescription monitoring It is well accepted that the increasing harm and deaths from the misuse of prescription medicines is a major public health concern in Victoria. In 2016, there were 372 Victorian drug overdose deaths involving pharmaceutical medicines, higher than the number of overdose deaths involving illicit drugs (257) and the road toll (291). 1 There has been an increasing push by coroners in Australia for the implementation of a mandatory realtime prescription monitoring system (RTPM) that alerts doctors and pharmacists to people who are misusing prescription drugs. 2 In a response to the coroners recommendations, the Victorian Government introduced legislation for a RTPM system to be rolled out in The Drugs, Poisons and Controlled Substances Amendment (Real-time Prescription Monitoring) Act 2017 (Vic) (the Act) was passed on 19 October 2017 and is expected to commence on 1 August The Act establishes the legislative framework that will underpin Victoria s RTPM system, which provides doctors, nurse practitioners and pharmacists with access to the system and allows them to review up-to-date information on the prescriptions histories of the patients in their care. 4 The RTPM system, to be known as SafeScript, will allow pharmacy dispensing records for certain medicines to be transmitted in real-time to a centralised database which allows doctors and pharmacists to access the up-to-the-minute medication prescription history of certain high risk medicines for their patient at the point of consultation. 5 SafeScript will monitor all Sch 8 medicines (as prescribed in the Drugs, Poisons and Controlled Substances Act 1981 (Vic) (DPCS Act)) such as morphine and oxycodone which carry the highest risk of misuse (monitored poisons), 6 and some Sch 4 medicines, including all benzodiazepines such as diazepam and quetiapine. 7 It will also streamline the existing Sch 8 permit requirements to reduce duplication and regulatory burden. 8 Objectives of the Act The purpose of the Act is the prevention of prescription drug overdoses and earlier detection of prescribed medicine misuse. 9 The main objectives of the Act are to amend the DPCS Act and to: empower the Secretary of the Department of Health and Human Services (Department) to establish a database containing records of the supply of all monitored poisons 10 provide the Secretary with the power to require a prescribed person, class of person or data source entity to provide information to the database in accordance with the regulations 11 enable access, use and disclosure of information on the monitored poisons database by: pharmacists, registered medical practitioner or nurse practitioners for purposes specified in the Act 12 prescribed entities or person authorised by the Secretary (or class of such entities or persons) for purposes prescribed in the regulations or the authorisation 13 Mandatory requirements under the Act Under the Act, registered medical practitioners, pharmacists, nurse practitioners and authorised suppliers will be required to review a patient s dispensing history on SafeScript before writing, dispensing or supplying a prescription (exceptions apply in circumstances where the risk of prescription shopping is low, such as in prisons, residential aged care or as hospital inpatients). 14 A penalty of more than $15,000 applies to practitioners who do not take reasonable steps to check the monitored poisons database before prescribing or supplying the monitored poisons (100 penalty units). 15 Reportable drug event The Act also requires a registered medical practitioner, pharmacist or nurse practitioner to notify the Secretary as soon as practicable of a reportable drug event. 16 2

2 A reportable drug event is defined as: for a pharmacist, when a request is received for the sale, supply or dispense of any drug of dependence from Sch 8, Sch 9 or Sch 4 that are either in greater quantities, or more frequently than reasonably necessary 17 for a registered medical practitioner, when there is a reason to believe that the patient is a drugdependent person in circumstances where: the patient requests or seeks Sch 9 drugs the medical practitioner intends to treat or is treating the patient with a Sch 9 drug 18 The Act responds to coroners calls for implementation of RTPM in Victoria A number of Victorian coroners had recommended the implementation of a RTPM in an attempt to reduce the number of lives that are lost as a result of overdosing on prescription medications. The next section explores some of the findings into deaths due to prescription medication overdose and considers whether the Act has addressed the concerns raised by the coroner in those decisions. Case of Ms B Ms B was a 44-year-old woman who had a psychiatric condition and was a heroin user. 19 At the time of her death in December 2011, police found several prescription medications at her home in a kitchen cupboard. No illicit drugs were found. 20 The cause of Ms B s death was intoxication by the combined effects of tramadol, methadone, diazepam, codeine, alprazolam, risperidone, doxepin and metoclopramide. 21 The toxicology report also noted that the concurrent use of depressant drugs such as benzodiazepines and other opioids might have contributed to the toxicity of methadone. 22 Ms B had a complex mental history, including schizophrenia, depression and anxiety and was dependent on prescriptions for pain management. 23 In 2011, Ms B was repeatedly prescribed the same analgesic, anti-anxiety and antidepressant medications from seven different general practitioners and had received treatment for opiate dependence in the form of takeaway methadone doses. 24 Coroner s recommendations The State Coroner commented that if the RTPM system was in place at the time of Ms B s death, it would have enabled all of the clinicians involved in her care to make better-informed decisions about her. His Honour further stated that whilst it cannot be determined with certainty that the successful operation of the RTPM system would have saved her life, the potential for a different outcome remains. 25 His Honour made the following recommendations: that the Victorian Department of Heath progress the implementation of a Victorian-based [RTPM] system as a matter of urgency to prevent ongoing harms and deaths prescribing and dispensing of pharmaceutical drugs. 26 that while the Victorian Department of Health continues with its efforts to implement a [RTPM system] for Schedule 8 drug dispensing, it [should also identify] the legislative and regulatory barriers that might prevent drugs listed in other schedules (particularly Schedule 4) from being monitored within the scope of the program[,] [so as to] enhance clinicians ability to make appropriate clinical decisions about patients. 27 that the Victorian Department of Heath consider meeting with private health information technology developers and vendors to discuss and, if appropriate, address the legislative and regulatory barriers that might prevent private companies providing [RTPM] capacity through their products and services. 28 Case of Mr A Mr A died on 23 September 2010 when he was 34 years old. At the time of death, police located drug paraphernalia as well as numerous prescription medications and scripts in his bedroom. 29 The cause of Mr A s death was mixed drug overdose (heroin, methadone, codeine, diazepam, nitrazepam, oxazepam and doxepin). 30 Mr A had a longstanding history of illicit drug use and prescription drug abuse dating back to early adolescence. 31 Coroner Olle identified Mr A s drug seeking behaviour as attending numerous doctors with the aim of obtaining benzodiazepines, including nitrazepam, oxazepam and diazepam and the opiate pain reliever tramadol. 32 For a significant period of time leading up to his death, Mr A was engaged in prescription shopping by attending multiple doctors to obtain pharmaceutical drugs of dependence in excess of his therapeutic need. 33 Coroner Olle commented that Victorian coroners have advocated the need for a functioning RTPM system in Victoria to assist medical practitioners in coordinating their care for patients and to reduce the harm and deaths associated with pharmaceutical drugs. 34 His Honour further commented that such a system can be of significant benefit for medical practitioners involved in the case of patients such as Mr A, as it can alert them to each other s existence and to the fact that the patient has been prescribed and dispensed prescription medications well above the therapeutic need. 35 In line with the recommendations published by State Coroner in the finding into the death of Ms B, Coroner Olle reiterated the urgent need for the implementation of the RTPM system for Sch 8 drugs and 3

3 some Sch 4 drugs. The Coroner further recommended that the Australian Government Department of Human Services should review how Medicare Australia responds to medical practitioners Prescription Shopping Information Service 36 queries, to ensure that medical practitioners can appropriately identify a prescription shopper and to assist medical practitioners with making appropriate notifications as required under the DPCS Act. 37 Case of Mr W Mr W was a 30-year-old male who had a psychiatric condition and was regularly prescribed a combination of antipsychotic medication, narcotic analgesic and codeine. 38 Mr W died on 25 February 2011, and at the time of his death, several packets of prescription medications were found in his house, including: 39 benzodiazepines (Temaze, Alodorm, Alepam, Antenex) opioid analgesics (Codapane and Panadeine Forte) antipsychotics (Seroquel and Risperdal) antidepressants antiemetics antihypertensives antibiotics The cause of Mr W s death was mixed drug toxicity involving codeine, tramadol, oxazepam and diazepam. 40 Mr W had a complex medical history including: 41 bipolar affective disorder schizophrenia anxiety depression back pain secondary to spinal injuries sustained in traffic accidents previous opiate and benzodiazepine dependence excessive alcohol use absent right kidney previous heroin encephalopathy Mr W engaged in prescription shopping for multiple pharmaceutical drugs involving multiple prescribing doctors, medical practices and pharmacies. For example, in the 6 months prior to his death, Mr W attended at least 21 doctors practising from seven different medical clinics to obtain scripts for prescription-only drugs 42. Coroner s recommendations Relevantly, Coroner Spanos observed that numerous coronial investigations conducted over the last decade attest to the fact that curtailing prescription shopping requires a comprehensive, systematic and real-time solution to the information deficit that impedes coordination of medical care. 43 Her Honour further commented that for more than a decade in Victoria, coroners had recommended the development and implementation of the RTPM system to prevent ongoing harm and deaths prescribing and dispensing of pharmaceutical drugs. Her Honour stated that Mr W s death again highlighted the benefits such a scheme could have in saving lives. 44 In line with the recommendations published by the State Coroner in the finding into the death of Ms B, Coroner Spanos urged the Victorian Department of Health to progress the implementation of the RTPM system. 45 Her Honour also recommended that the Royal Australian College of General Practitioners should consider including and enhancing a section in its Standards for General Practices 46 to inform and advise general practitioners about their legal obligations when prescribing medications under the DPCS Act and to provide opportunities for professional development relating to the safe prescription of drugs of dependence to both drug-dependent and non-drug-dependent patients. 47 Does the Act address the issues identified by the coroners? These coronial decisions highlight the common issue amongst deceased persons: that they engaged in prescription shopping for multiple pharmaceutical drugs involving multiple prescribing doctors, medical practices and pharmacies, and that there were no systems in place at the time to alert the health professionals to this fact. One of the prominent observations of the coroners in each of the coronial findings was the need for the implementation of a Victorian-based RTPM system as a matter of urgency to prevent ongoing harm and deaths prescribing and dispensing of pharmaceutical drugs. The introduction of the Act addresses the issues raised by the coroners by implementing the RTPM system and allowing medical practitioners, nurse practitioners and pharmacists to access the up-to-the-minute medication prescription history of the monitored poisons. This will help improve communication and coordination of care between health professionals and assist with their clinical decision-making process and it may also provide opportunities for counselling and intervention where necessary. The Act also addresses the concerns relating to the monitoring of drugs other than Sch 8 poisons, such as Sch 4 drugs and other drugs of dependence. The scheme allows the Secretary of the Department to prescribe that 4

4 certain drugs are to be monitored by the system, which in turn will mean that SafeScript can be constantly evolving to reflect changes in prescription shopping behaviour. The majority of the other recommendations rely mainly on increased training and professional development for health professionals who deal with at-risk patients. The Victorian Government has announced it will deliver training to health professionals as part of the implementation program for the Act. 48 Conclusion Health practitioners face challenges everyday with the task of balancing effective management of their patients medical conditions while at the same time preventing the serious risks of dependence and misuse of prescription drugs. The implementation of the RTPM system will help address the issues raised by the coroners and assist health professionals to manage prescription shoppers more effectively, thereby reducing the ongoing harm and deaths associated with pharmaceutical drug misuse and inappropriate prescribing and dispensing of pharmaceutical drugs. However, it is important to note that the issue of identifying patients with the risk of prescription drug misuse and addiction is a complex one and requires a broad solution. As observed by Coroner Spanos in a number of coronial investigations, the issue of prescription shopping requires a comprehensive, systematic and real-time solution. 49 It is essential that RTPM system does not prevent effective treatment when needed and that there are appropriately-funded drug addiction and counselling services to refer patients. It will also be very important that health professionals are provided with ongoing training regarding the new legal framework and on the use of SafeScript to ensure that they understand and comply with their obligations under the Act. Angela Liu Law Graduate Russell Kennedy Lawyers Footnotes 1. Department of Health and Human Services, SafeScript, 2017, www2.health.vic.gov.au/public-health/drugs-and-poisons/ safescript. 2. See for example E Turner Coronial inquests call for urgent implementation of real-time prescription monitoring to prevent ongoing harms and deaths from the combined effects of benzodiazepines and methadone replacement therapy (2015) 23(3) HLB Minister for Health, Victoria Life-saving real-time prescription monitoring laws pass parliament media release (19 October 2017) /10/ Life-Saving-Real-Time-Prescription-Monitoring- Laws-Pass-Parliament.pdf; Explanatory Memorandum, Drugs, Poisons and Controlled Substances Amendment (Real-time Prescription Monitoring) Bill 2017 (Vic) cgi-bin/download.cgi/cgi-bin/download.cgi/download/au/legis/ vic/bill_em/dpacsapmb pdf. 4. Above. 5. Above n Drugs, Poisons and Controlled Substances Amendment (Realtime Prescription Monitoring) Act 2017, s Victoria, Parliamentary Debates, Legislative Council, 9 August 2017, , (Jill Hennessy); Life-saving realtime prescription monitoring laws pass parliament, above n Above. 9. Victoria, Parliamentary Debates, Legislative Council, 17 October 2017, (Jeffrey Wooldridge). 10. Drugs, Poisons and Controlled Substances Amendment (Realtime Prescription Monitoring) Act 2017, ss 1 and 5 DPCS Act, s 30A(1). 11. Above, ss 1 and 5 DPCS Act, s 30B(2). 12. Above n 10, ss 1 and 5 DPCS Act, s 30C(1) (2). 13. Above n 10, s 5 DPCS Act, s 30C(3) (5). 14. Above n 10, s 5 DPCS Act, s 30E 30H, s 9 DPCS Act, s 34D, s 10 DPCS Act, s 34F(c) and s 11 DPCS Act, s 35A. 15. Above n 10, s 5 DPCS Act, s 30E 30H. 16. Above n 10, s 7 DPCS Act, s 32A. 17. Above n 10, s 7 DPCS Act, s 32A(2)(a). 18. Above n 10, s 7 DPCS Act, s 32A(2)(b). 19. Coroners Court (Vic) Inquest into the death of Anne Christine Brain (30 October 2014) paras 1 and 4 (Inquest) above n Inquest, above, para Inquest, above n 19, para Inquest, above n 19, para Inquest, above n 19, para Inquest, above n 19, paras Inquest, above n 19, comment Inquest, above n 19, recommendation Inquest, above n 19, recommendation Inquest, above n 19, recommendation Coroners Court (Vic) Finding into death without inquest: Jamie Laurence Apap (24 Jul 2015) para 14 jamielaurenceapap_ pdf. 30. Above, para Above n 29, para Above n 29, para Above n 29, para Above n 29, para 34. 5

5 35. Above n 29, para Available at Above n 29, recommendation Coroners Court (Vic) Finding into the death without inquest: Dean Wayne Wright (18 January 2016) para 2 deanwaynewright_ pdf. 39. Above, paras Above n 38, para Above n 38, para Above n 38, para Above n 38, para Above n 38, comment Above n 38, recommendations Royal Australian College of General Practitioners, Standards for General Practices, 4th edn, Royal Australian College of General Practitioners College House, Victoria, Above n 38, recommendations Above n Above n 38, para 60. 6

Emma Turner RUSSELL KENNEDY LAWYERS

Emma Turner RUSSELL KENNEDY LAWYERS Coronial inquests call for urgent implementation of real-time prescription monitoring to prevent ongoing harms and deaths from the combined effects of b e n z o d i a z e p i n e s a n d m e t h a d o

More information

REAL TIME MONITORING OF PRESCRIPTION MEDICINES BEING A HEALTHY STATE

REAL TIME MONITORING OF PRESCRIPTION MEDICINES BEING A HEALTHY STATE BEING A HEALTHY STATE 2036 WILL MARK OUR STATE S BICENTENARY By the time our State turns 200 years old, I want South Australia to be a place of prosperity. Planning and delivering on my vision for a better

More information

Prescribing drugs of dependence

Prescribing drugs of dependence Prescribing drugs of dependence Prescribing drugs of dependence Avant supports: à Education and guidelines for practitioners about the legal obligations in prescribing drugs of dependence à Development

More information

Prescribing Perils including - drugs of dependence RACGP Conference - September 2015

Prescribing Perils including - drugs of dependence RACGP Conference - September 2015 Prescribing Perils including - drugs of dependence RACGP Conference - September 2015 Dr Greg Whelan AM MD, MBBS MSc., FRACP, FAFPHM, FAChAM Senior Medical Advisor, Avant Insurance Dr Owen Bradfield MBBS(Hons),

More information

Pharmaceutical Drugs & Real-Time Prescription Monitoring.

Pharmaceutical Drugs & Real-Time Prescription Monitoring. Pharmaceutical Drugs & Real-Time Prescription Monitoring. 1 What is Real-Time Prescription Monitoring? Real-Time Prescription Monitoring enables prescribing doctors and dispensing pharmacists to access

More information

New regulatory requirements DPCS Regulations 2017

New regulatory requirements DPCS Regulations 2017 New regulatory requirements DPCS Regulations 2017 Prescribers and pharmacists May 2017 Table of Contents Explanatory notes... 1 Clarifying the meaning of key terms... 1 Chart instructions and prescriptions...

More information

Review of Controlled Drugs and Substances Act

Review of Controlled Drugs and Substances Act Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A

More information

Safe Prescribing and Dispensing of Controlled Drugs. Joint Guidance Medical Council and Pharmaceutical Society of Ireland

Safe Prescribing and Dispensing of Controlled Drugs. Joint Guidance Medical Council and Pharmaceutical Society of Ireland Safe Prescribing and Dispensing of Controlled Drugs Joint Guidance Medical Council and Pharmaceutical Society of Ireland Purpose of this Guidance Purpose of this Guidance This resource aims to facilitate

More information

Drug-related deaths and deaths among drug users in Ireland figures from the National Drug-Related Deaths Index

Drug-related deaths and deaths among drug users in Ireland figures from the National Drug-Related Deaths Index Drug-related deaths and deaths among drug users in Ireland 21 figures from the National Drug-Related Deaths Index January 213 Summary of 21 results This update presents figures from the National Drug-Related

More information

Medicare Advantage Outreach and Education Bulletin

Medicare Advantage Outreach and Education Bulletin Medicare Advantage Outreach and Education Bulletin Blue Cross and Blue Shield of Georgia Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain

More information

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System Our Journey to Addressing the PA PDMP Program Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System 1 Geisinger Health System Geisinger Health System is an integrated

More information

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin

More information

Ontario s Narcotics Strategy

Ontario s Narcotics Strategy Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action

More information

Table of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004

Table of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004 OXYCONTIN TASK FORCE INTERIM REPORT January 30, 2004 Submitted to Hon. Elizabeth Marshall, Minister of Health & Community Services, Government of Newfoundland and Labrador Table of Contents INTRODUCTION

More information

Public Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy

Public Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy Public Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy Key message: PHAA will 1. Support strategies focused primarily on preventing or delaying the onset of drug misuse,

More information

Regulations for the prescribing of Schedule 8 medicines in WA

Regulations for the prescribing of Schedule 8 medicines in WA Regulations for the prescribing of Schedule 8 medicines in WA Pharmaceutical Services Branch V: C20131218AG-2 Aims of presentation To focus Schedule 8 (S8) medication regulations for prescribers on: prescribing

More information

I am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the

I am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the MINISTERIAL STATEMENT TO THE HOUSE OF ASSEMBLY BY THE HONOURABLE KIM N. WILSON, JP, MP MINISTER OF HEALTH UPDATES AND MODERNIZATION OF DRUG SCHEDULES 24 November 2017 Mr Speaker and Honourable Members,

More information

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director

More information

Drug Profiles of Apprehended Drivers in Victoria

Drug Profiles of Apprehended Drivers in Victoria Drug Profiles of Apprehended Drivers in Victoria J Gerostamoulos, P McCaffrey, O H. Drummer and M Odell*. Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, 57-83

More information

Appendix F Federation of State Medical Boards

Appendix F Federation of State Medical Boards Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction

More information

A Bill Regular Session, 2015 SENATE BILL 717

A Bill Regular Session, 2015 SENATE BILL 717 Stricken language would be deleted from and underlined language would be added to present law. 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session, SENATE BILL By: Senator

More information

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment

More information

Mark W. Caverly, Chief Liaison and Policy Section

Mark W. Caverly, Chief Liaison and Policy Section DEA Issues: An Update Harold Rogers National Prescription Drug Monitoring Meeting Meeting September 24 25, 2009 Mark W. Caverly, Chief Liaison and Policy Section Prescription Drug Abuse Prescription Drug

More information

Drug-related deaths and deaths among drug users in Ireland figures from the National Drug-Related Deaths Index

Drug-related deaths and deaths among drug users in Ireland figures from the National Drug-Related Deaths Index Drug-related deaths and deaths among drug users in Ireland 2011 figures from the National Drug-Related Deaths Index January 2014 Summary of 2011 results This update presents figures from the National Drug-Related

More information

Who is at risk of misusing pharmaceuticals? Overdose in Victoria. But I don t have a drug problem 10/18/2018. Rates of opioid prescribing

Who is at risk of misusing pharmaceuticals? Overdose in Victoria. But I don t have a drug problem 10/18/2018. Rates of opioid prescribing But I don t have a drug problem Engaging With Consumers Affected By Medication Misuse How many people reported misusing a medication in the past year? What percentage of people who misuse medication are

More information

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Virginia. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Oregon s PDMP: An epidemiological assist tool

Oregon s PDMP: An epidemiological assist tool Oregon s PDMP: An epidemiological assist tool Todd Beran Center for Prevention and Health Promotion Oregon Health Authority PDMP TTAC Webinar February 13, 2013 1 Acknowledgements Lisa Millet, MSH, Section

More information

NC General Statutes - Chapter 90 Article 5E 1

NC General Statutes - Chapter 90 Article 5E 1 Article 5E. North Carolina Controlled Substances Reporting System Act. 90-113.70. Short title. This Article shall be known and may be cited as the "North Carolina Controlled Substances Reporting System

More information

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Controlled Substances Board

Controlled Substances Board Controlled Substances Board Report 1 July 1 September 30, 2016 Contact Information Wisconsin Controlled Substances Board Chairperson: Doug Englebert Members: Englebert, Doug, Chairperson Bloom, Alan, Vice

More information

California. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Amendments to the Mental Health Act 1986 (Vic) regarding involuntary treatment and Community Treatment Orders

Amendments to the Mental Health Act 1986 (Vic) regarding involuntary treatment and Community Treatment Orders Health Legal Pty Ltd ABN 52 104 156 694 Level 1, 499 St Kilda Road Melbourne Vic 3004 Phone: 03 9861 4001 Fax: 03 9867 8580 www.healthlegal.com.au Amendments to the Mental Health Act 1986 (Vic) regarding

More information

Public Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy

Public Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy Public Health Association of Australia: Policy-at-a-glance Pharmaceutical Drug Misuse Policy Key message: Summary: Audience: Responsibility: 1. Pharmaceutical drugs, when used as intended as part of quality

More information

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system

Medicinal cannabis. What is medicinal cannabis? What are cannabinoids? The endocannabinoid system Medicinal cannabis What is medicinal cannabis? Broadly speaking, medicinal cannabis is cannabis prescribed to relieve the symptoms of a medical condition, such as epilepsy. It is important to make the

More information

Barbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County

Barbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County County West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report County The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with

More information

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Safe Prescribing of Drugs with Potential for Misuse/Diversion College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines

More information

International Drug Control Conventions. Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol

International Drug Control Conventions. Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol 18 October 2016 International Drug Control Conventions Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol Convention on Psychotropic Substances of 1971 United Nations Convention

More information

Mingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Mingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board

More information

Pennsylvania Prescription Drug Monitoring Program Trends,

Pennsylvania Prescription Drug Monitoring Program Trends, DEA Intelligence Report Brief DEA-PHL-DIR-006-17 Pennsylvania Prescription Drug Monitoring Program Trends, 2014-2015 December 2016 1 Executive Summary The abuse and diversion of pharmaceutical drugs, particularly

More information

Putnam County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Putnam County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board

More information

Opioids drive continued increase in drug overdose deaths

Opioids drive continued increase in drug overdose deaths CDC: Drug overdose deaths increase for 11th consecutive year Opioids drive continued increase in drug overdose deaths Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th

More information

The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose

The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose The Regulatory Agency Will See You Now Kevin L. Zacharoff, MD Disclosures Nothing to Disclose 1 Learning Objectives Identify pain treatment related regulatory agencies Discuss the changing role of regulatory

More information

Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D.

Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D. Running Head: MEDICATION-ASSISTED TREATMENT ATTITUDES Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program Caroline Allison Dr. Kathleen Moore, Ph.D. Department of Mental Health Law

More information

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin. The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp

More information

Pocahontas County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Pocahontas County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board

More information

Kanawha County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Kanawha County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board

More information

SULLIVAN COUNTY Drug Abuse Prevention Task Force

SULLIVAN COUNTY Drug Abuse Prevention Task Force SULLIVAN COUNTY Drug Abuse Prevention Task Force Joseph A. Todora LMSW, Commissioner Sullivan County Division of Health ans Family Servies 17 Community Lane Liberty, NY 12754 MISSION: The mission of the

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Prescribing and Dispensing Drugs

Prescribing and Dispensing Drugs STANDARDS & GUIDELINES Prescribing and Dispensing Drugs TABLE OF CONTENTS Standards and guidelines inform practitioners and the public of CDSBC s expectations for registrants. This document primarily contains

More information

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference

Ministry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference Ministry of Health and Long-Term Care Presentation to the CPSO Methadone Prescribers Conference November 9, 2012 Overview Minister s Expert Working Group on Narcotic Addiction OxyNEO and OxyContin: Changes

More information

ASPMN Conference Baltimore, Maryland

ASPMN Conference Baltimore, Maryland ASPMN Conference Baltimore, Maryland Prescribing Controlled Substances Managing Risk and Optimizing Outcomes September 13, 2012 Tracey Fremd, NP Tracey Fremd Consulting, Inc. Most Common Uses for Controlled

More information

Curbing Prescription Drug Abuse in Medicaid

Curbing Prescription Drug Abuse in Medicaid Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance

More information

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Summary This quality standard provides guidance on the appropriate prescribing, monitoring, and tapering of opioids to treat

More information

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016 1 Opioid Abuse in Iowa Rx to Heroin Iowa Governor s Office of Drug Control Policy January 2016 Why Is This Important? 2 3 National Rx Painkiller Trends CDC, 2013 4 National Rx-Heroin Trends NIH, 2015 5

More information

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators Report The West Virginia Violence and Injury Prevention Program ( VIPP), in collaboration with the West Virginia Board

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

1. Introduction. 2. Role of PSI as Pharmacy Regulator

1. Introduction. 2. Role of PSI as Pharmacy Regulator 1. Introduction 1.1. I would like to begin by thanking the Committee for inviting the Pharmaceutical Society of Ireland here today to assist in the Committee s on-going scrutiny of the Cannabis for Medicinal

More information

NCIS Coding Tips. Coding Alcohol and Drug Related Deaths

NCIS Coding Tips. Coding Alcohol and Drug Related Deaths NCIS Coding Tips Coding Alcohol and Drug Related Deaths In terms of NCIS coding, alcohol and drugs may be involved in a death in the following ways: The primary cause of a death, i.e. drug overdose OR

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid

More information

Effects of Drugs (Other than A lcohol) on Road Safety in V ictoria

Effects of Drugs (Other than A lcohol) on Road Safety in V ictoria Effects of Drugs (Other than A lcohol) on Road Safety in V ictoria J o h n R ic h a r d so n M P V ic to ria n P a rlia m e n t R o ad S a fe ty C o m m itte e, S p rin g S tre e t, M e lb o u rn e 3 0

More information

Alcohol, Tobacco and Other Drugs Minimum Standard. April 2015

Alcohol, Tobacco and Other Drugs Minimum Standard. April 2015 Alcohol, Tobacco and Other Drugs Minimum Standard April 2015 Contents 1 Executive Summary... 2 2 More Information... 2 3 Using this Standard... 2 4 Standard Provisions... 2 4.1 Legislative Requirements...

More information

West Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

West Virginia. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile West Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Drugs and Alcohol Abuse Policy

Drugs and Alcohol Abuse Policy Drugs and Alcohol Abuse Policy Introduction From the beginning of 2013, there are increased requirements to provide mandatory proof of inhouse drugs and alcohol testing procedures prior to employees being

More information

SCHEDULE 2 THE SERVICES

SCHEDULE 2 THE SERVICES SCHEDULE 2 THE SERVICES A. Service Specifications Mandatory headings 1 4: mandatory but detail for local determination and agreement Optional headings 5-7: optional to use, detail for local determination

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions

More information

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES TITLE 16 CHAPTER 10 PART 14 OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES 16.10.14.1 ISSUING AGENCY: New

More information

Recommendations for Components of Emergency Department Discharge Protocols

Recommendations for Components of Emergency Department Discharge Protocols Recommendations for Components of Emergency Department Discharge Protocols Background Maryland, like many other states, is in the midst of an opioid crisis. In 2016, 89 percent of all intoxication deaths

More information

Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No.

Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No. Submission to the Senate Community Affairs Legislation Committee inquiry into the Therapeutic Goods Amendment (2016 Measures No. 1) Bill 2016 Submitted by: Submitted electronically to: Complementary Medicines

More information

Requirements for the prescribing of Schedule 4 and Schedule 8 Medicines in Western Australia

Requirements for the prescribing of Schedule 4 and Schedule 8 Medicines in Western Australia Requirements for the prescribing of Schedule 4 and Schedule 8 Medicines in Western Australia Pharmaceutical Services Branch June 2008 1 Key Points Prescribing Schedule 4 medicines (S4s) S4 prescriptions

More information

Re: Handling of gabapentin and pregabalin as Schedule 3 Controlled Drugs in health and justice commissioned services

Re: Handling of gabapentin and pregabalin as Schedule 3 Controlled Drugs in health and justice commissioned services To: Health and justice commissioners and providers Public Health England health and justice leads Her Majesty s Prison and Probation Service Home Office immigration removal centre leads Health and justice

More information

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-FIRST REGULAR SESSION April 24-26, 2017 Washington, D.C. OEA/Ser.L/XIV.2.61 CICAD/doc.2299/17 21 April 2017 Original: English CANADA S OPIOID

More information

Workplace Drug and Alcohol Policy

Workplace Drug and Alcohol Policy Workplace Drug and Alcohol Policy January 2017 This Drug and Alcohol Policy is intended for and includes but is not limited to all Students, Contractors and all others either directly or indirectly engaged

More information

UTAH S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB)

UTAH S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB) UTAH S CONTROLLED SUBSTANCE DATABASE PROGRAM (CSDB) Harold Rogers Prescription Drug Monitoring Program National Meeting Washington, D.C. August 17 August 19 th, 2016 Marvin H. Sims, C.S. DataBase Administrator

More information

Pharmaceutical Misuse and its Challenges: Opioid Use in Ontario. Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012

Pharmaceutical Misuse and its Challenges: Opioid Use in Ontario. Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012 Pharmaceutical Misuse and its Challenges: Opioid Use in Ontario Ontario Harm Reduction Conference Tara Gomes Tuesday January 31, 2012 Objectives To review the prescription opioid crisis To understand the

More information

High Risk Medicines Prescribing Policy. July 2017

High Risk Medicines Prescribing Policy. July 2017 High Risk Medicines Prescribing Policy July 2017 Responsible Committee: Quality Committee Date Effective: July 2017 Author: Rahinatu Amadu Supersedes: July 2016 Next Review Due: July 2018 1. INTRODUCTION

More information

National Drug-Related Deaths Index

National Drug-Related Deaths Index HRB Bulletin Drug Deaths 2015 National Drug-Related Deaths Index 2004 to 2015 data Overview This update presents figures from the National Drug- Related Deaths Index (NDRDI) on deaths due to poisoning

More information

Substance use and misuse

Substance use and misuse An open learning programme for pharmacists and pharmacy technicians Substance use and misuse Educational solutions for the NHS pharmacy workforce DLP 160 Contents iii About CPPE open learning programmes

More information

Proposal for a COUNCIL IMPLEMENTING DECISION

Proposal for a COUNCIL IMPLEMENTING DECISION EUROPEAN COMMISSION Brussels, 18.12.2017 COM(2017) 765 final 2017/0345 (NLE) Proposal for a COUNCIL IMPLEMENTING DECISION on subjecting the new psychoactive substance methyl 1-(2-phenylethyl)-4- [phenyl(propanoyl)amino]piperidine-4-carboxylate

More information

ScO.S. Academic Detailing for Safer Prescribing

ScO.S. Academic Detailing for Safer Prescribing ScO.S. Academic Detailing for Safer Prescribing Sarah Ball, PharmD Research Assistant Professor MUSC College of Medicine September 6, 2017 Megan Pruitt, PharmD SCORxE Clinical Pharmacy Consultant MUSC

More information

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation. Pharmacy Law 2016 Ronda H. Lacey, J.D., M.S. Pharm Disclosure Statement I have no conflicts of interest to disclose related to this presentation. Objectives At the conclusion of this continuing education

More information

Medicare Advantage Outreach and Education Bulletin

Medicare Advantage Outreach and Education Bulletin Medicare Advantage Outreach and Education Bulletin Anthem Blue Cross and Blue Shield Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain management.

More information

Ontario s Narcotics Strategy

Ontario s Narcotics Strategy Ontario Public Drug Programs Division Ontario s Narcotics Strategy Frequently Asked Questions This fact sheet provides basic information only. It must not take the place of medical advice, diagnosis or

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid

More information

Risk Evaluation And Mitigation Strategies:

Risk Evaluation And Mitigation Strategies: Risk Evaluation And Mitigation Strategies: The Experts Answer Questions from Health-System Pharmacists A midday symposium about the risk evaluation and mitigation strategies (REMS) required by the Food

More information

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease Evidence-Based Clinical Practice Guideline Treatment & Management of Ocular Disease Effective November 29, 2017 Treatment & Management Of Ocular Disease Clinical Practice Guideline The objective of this

More information

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and effective. Before any drug is approved for marketing

More information

TRIM reference DD17/ Endorsed by Publication date Review date

TRIM reference DD17/ Endorsed by Publication date Review date Participant procedure: drug Procedures provide practical step by step guidance to describe processes and actions required to enable the implementation of a policy or guideline. They can also be developed

More information

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Utah. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Utah Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view

More information

RE: PROPOSED AMENDMENTS TO REGULATIONS TO THE CONTROLLED DRUGS AND SUBSTANCES ACT

RE: PROPOSED AMENDMENTS TO REGULATIONS TO THE CONTROLLED DRUGS AND SUBSTANCES ACT November 8, 2017 Ms. Michelle Boudreau Director General Controlled Substances Directorate Office of Legislative and Regulatory Affairs Health Canada 150 Tunney s Pasture Driveway, Main Stats Building Address

More information

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

On December 27, 2017, the Lieutenant Governor signed into law several new requirements OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following

More information

Monash University Procedure. High Risk Scheduled Drugs and Poisons Procedure (S8/9/11)

Monash University Procedure. High Risk Scheduled Drugs and Poisons Procedure (S8/9/11) Monash University Procedure Procedure Title Parent Policy High Risk Scheduled Drugs and Poisons Procedure (S8/9/11) OHS Policy Date Effective 19 September 2017 Review Date September 2020 Procedure Owner

More information

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion Fraud and Compliance Forum, October 2017. Click here to access audio. AHLA X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion Michelle Bergholz Frazier Senior Vice President,

More information

Coversheet: Medicinal cannabis: 100 day action

Coversheet: Medicinal cannabis: 100 day action Coversheet: Medicinal cannabis: 100 day action Advising agencies Decision sought Proposing Ministers Ministry of Health Introduction of Misuse of Drugs Amendment Bill Hon Dr David Clark, Minister of Health

More information

Victorian Parliamentary Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017

Victorian Parliamentary Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 Victorian Parliamentary Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 19 April 2017 That the Government: VHA Recommendations

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy

More information

Michael M. Miller, MD, FASAM, FAPA

Michael M. Miller, MD, FASAM, FAPA Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical

More information

Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof

Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof Issuer: Riigikogu Type: act In force from: 13.05.2016 In force until: 22.11.2018 Translation published: 06.05.2016 Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof Amended by the

More information